J. Grem

发表

NCCN Clinical Practice Guidelines in Oncology: colon cancer.

M. Choti, J. Fleshman, C. Willett, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

M. Choti, C. Willett, Yi-Jen Chen, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Ahmed Kamel, Howard S Hochster, Christopher G Willett, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.

J. Willson, J. Grem, D. Trump, 1990, Cancer research.

A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.

S. Steinberg, S. Arbuck, J. Grem, 1993, Cancer research.

Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.

A. Monks, J. Grem, C. Allegra, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response

Emalie J. Clement, M. Hollingsworth, J. Grem, 2019, Clinical Cancer Research.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Robert E Denroche, Hans Clevers, Gokce Askan, 2018, Cancer discovery.

Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.

B. Leyland-Jones, J. Grem, J. M. Hamilton, 1987, Cancer treatment reports.

Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.

J. Grem, C. Allegra, E. Chu, 1992, Seminars in oncology.

Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells.

J. Grem, D. Nguyen, B. Monahan, 1999, Biochemical pharmacology.

Clinical features and natural history of intramedullary spinal cord metastasis

J. Grem, D. Trump, J. Burgess, 1985, Cancer.

Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography.

L. Neckers, C. Takimoto, J. Grem, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy

J. Grem, M. Blackman, B. Monahan, 2003, Integrative cancer therapies.

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development

J. Grem, 2000, Investigational New Drugs.

Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography.

C. Takimoto, J. Grem, C. Allegra, 1994, Journal of chromatography. B, Biomedical applications.

Rectal Cancer

M. Choti, A. Benson, C. Willett, 2018, Springer International Publishing.

Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.

J. Grem, C. Allegra, 1990, Cancer research.

Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.

L. Rubinstein, J. Grem, J. Plowman, 1991, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells.

J. Grem, C. Allegra, J. Trepel, 1992, Biochemical pharmacology.

Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine.

J. Grem, P. Adamson, F. Balis, 1992, Cancer research.

Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts.

J. Grem, P. Adamson, F. Balis, 1993, Biochemical pharmacology.

Phase I clinical trial of continuous infusion cyclopentenyl cytosine

A. Chen, J. Grem, C. Allegra, 2004, Cancer Chemotherapy and Pharmacology.

Current treatment approaches in colorectal cancer.

J. Grem, 1991, Seminars in oncology.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Small Bowel Adenocarcinoma, Version 1.2020

J. Meyerhardt, A. Benson, C. Willett, 2019 .

A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin

A. Chen, C. Takimoto, J. Grem, 2003, Cancer Chemotherapy and Pharmacology.

5-Fluorouracil and Its Biomodulation in the Management of Colorectal Cancer

J. Grem, 2002 .

Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer.

J. Grem, 2001, Oncology.

University of Birmingham Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels

J. Grem, K. Brain, R. Wilson, 2005 .

Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage‐gated sodium channels

J. Grem, A. Vincent, K. Brain, 2005, British journal of pharmacology.

Monoclonal Antibodies in Colorectal Cancer: What We Know

J. Grem, Facp., 2007 .

Cardiac Toxicity Associated with Capecitabine Therapy

J. Grem, M. Wasif Saif, M. Quinn, 2003, Acta oncologica.

Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.

J. Grem, Yan Xu, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.

J. Grem, 1997, Seminars in oncology.

Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.

J. Grem, G. Leonard, M. Quinn, 2004, Anti-cancer drugs.

Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

J. Doroshow, C. Takimoto, J. Grem, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypersensitivity and idiosyncratic reactions to oxaliplatin

J. Grem, B. Schuler, M. Quinn, 2003, Cancer.

Acute oxaliplatin-induced peripheral nerve hyperexcitability.

M. Floeter, J. Grem, T. Lehky, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.

J. Grem, P. Fischer, 1989, Pharmacology & therapeutics.

The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.

S. Steinberg, J. Grem, C. Allegra, 1998, Oncology reports.

The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line.

P. Johnston, J. Grem, C. Allegra, 1996, European journal of cancer.

Sustained partial response of an intra-abdominal desmoid tumor treated with gemcitabine, 5-fluorouracil and leucovorin.

E. Szabo, J. Grem, B. Schuler, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.

J. Meyerhardt, C. Willett, Yi-Jen Chen, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Cephalotaxine esters: antileukemic advance or therapeutic failure?

B. Cheson, B. Leyland-Jones, J. Grem, 1988, Journal of the National Cancer Institute.

Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling

Quan P. Ly, Lynette M. Smith, S. Batra, 2021, EBioMedicine.

Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.

Quan P. Ly, J. Meza, J. Grem, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells.

J. Grem, C. Allegra, 1989, Journal of the National Cancer Institute.

Mature results of adjuvant colon cancer trials from the fluorouracil-only era.

J. Grem, 2004, Journal of the National Cancer Institute.

Colon cancer, version 3.2014.

James D. Murphy, C. Willett, Yi-Jen Chen, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Thymidylate synthase inhibitors.

J. Grem, A. S. Ismail, 2001, Cancer chemotherapy and biological response modifiers.

A phase 1 clinical trial of sequential pralatrexate followed by a 48‐hour infusion of 5‐fluorouracil given every other week in adult patients with solid tumors

J. Meza, J. Grem, J. Schwarz, 2015, Cancer.

Adjuvant therapy for colon cancer: a historical perspective.

J. Grem, 2004, Journal of the National Cancer Institute.

Cardiac complications observed in elderly patients following 2′‐deoxycoformycin therapy

M. Grever, J. Grem, S. A. King, 1991, American journal of hematology.

Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.

C. Takimoto, R. Diasio, J. Grem, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.

S. Steinberg, J. Grem, C. Allegra, 1992, Journal of the National Cancer Institute.

Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.

N. Petrelli, J. Grem, H. Douglass, 1987, Cancer treatment reports.

Metabolism and action of amino acid analog anti-cancer agents.

J. Grem, D. Cooney, Z. Hao, 1990, Pharmacology & therapeutics.

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.

B. Leyland-Jones, J. Grem, P. O'dwyer, 1988, Cancer research.

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

J. Doroshow, C. Takimoto, J. Grem, 2003, Seminars in oncology.

Doxorubicin: role in the treatment of osteosarcoma.

J. Grem, S. Blaney, M. Smith, 1993, Cancer treatment and research.

Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.

S. Steinberg, J. Grem, C. Allegra, 1995, Molecular pharmacology.

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

J. Meyerhardt, C. Willett, Yi-Jen Chen, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.

C. Takimoto, J. Grem, J. Shapiro, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.

M. Choti, J. Fleshman, C. Willett, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy

M. Floeter, J. Grem, T. Lehky, 2004, Muscle & nerve.

Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.

W. Hiddemann, J. Grem, C. Köhne, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anal carcinoma: Clinical practice guidelines in oncology™

M. Choti, J. Fleshman, J. Berlin, 2010 .

N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.

C. Takimoto, J. Grem, C. Allegra, 2001, Annals of Oncology.

High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.

D. Venzon, C. Takimoto, J. Grem, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

D. Venzon, C. Takimoto, J. Grem, 1997, Cancer Chemotherapy and Pharmacology.

Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.

J. Willson, J. Grem, D. Trump, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of 5‐fluorouracil, leucovorin, and interferon‐α in the treatment of patients with metastatic or recurrent gastric carcinoma

S. Lipsitz, M. Morrisey, A. Benson, 1999, Cancer.

Reversible increase in serum alpha-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma.

J. Grem, D. Trump, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

J. Meyerhardt, James D. Murphy, C. Willett, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Correlates of severe or life-threatening toxic effects from trimetrexate.

S. Ellenberg, J. Grem, S. A. King, 1988, Journal of the National Cancer Institute.

Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.

P. Johnston, J. Grem, C. Allegra, 1997, Oncology research.

Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.

S. Steinberg, D. Fraker, P. Johnston, 1995, The cancer journal from Scientific American.

Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.

S. Steinberg, A. Chen, S. Arbuck, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced cytotoxicity with interleukin-1α and 5-fluorouracil in HCT116 colon cancer cells

J. Grem, C. Allegra, F. Geoffroy, 1994 .

A phase II study of continuous infusion 5‐fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma

B. Kramer, D. Venzon, J. Grem, 1993, Cancer.

Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line.

J. Grem, C. Allegra, R. Mulcahy, 1989, Biochemical pharmacology.

Spontaneous remission in diffuse large cell lymphoma.

J. Grem, P. Carbone, J. H. Brandenburg, 1986, Cancer.

Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.

J. Grem, C. Allegra, F. Geoffroy, 1994, Oncology research.

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

J. Doroshow, C. Takimoto, J. Grem, 2007, Clinical Cancer Research.

Review: adjuvant hormonotherapy for breast cancer

J. Grem, P. Carbone, 1986 .

Treatment of mitomycin-associated microangiopathic hemolytic anemia with vincristine.

J. Grem, P. Carbone, J. Merritt, 1986, Archives of internal medicine.

Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells

J. Grem, K. Danenberg, P. Danenberg, 2002, Anti-cancer drugs.

Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil

J. Grem, R. Wilson, D. Dougherty, 2001, Anti-cancer drugs.

Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.

J. Grem, P. Fischer, 1986, Cancer research.

Modulation of fluorouracil metabolism and cytotoxicity by nitrothiobenzylinosine.

J. Grem, P. Fischer, 1986, Biochemical pharmacology.

Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.

J. Grem, C. Allegra, 1991, Biochemical pharmacology.

Adenocarcinoma-( Phosphonacetyl )-l-aspartate in Metastatic Gastrointestinal N Calcium Leucovorin in Combination with A Phase I Study of Continuous Infusion 5-Fluorouracil plus Updated

S. Steinberg, J. Grem, C. Allegra, 2006 .

Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.

J. Grem, G. Leonard, S. Zhuang, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacokinetic T rial o f W eekly O ral Fluorouracil G iven W ith E niluracil a nd Low-Dose L eucovorin t o P atients W ith S olid T umors

C. Takimoto, J. Grem, J. Shapiro, 2013 .

Phase I and Pharmacokinet ic Tria l o f Weekly Oral Fluorourac i l Given With Eni lurac i l and Low-Dose Leucovor in to Pat ients With Sol id Tumors

C. Takimoto, J. Grem, J. Shapiro, 2000 .

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility

P. Sorensen, T. Theander, M. Hollingsworth, 2016, Molecular Cancer Research.

Clinical use of thymidine as a rescue agent from methotrexate toxicity

M. Christian, J. Grem, S. A. King, 1991, Investigational New Drugs.

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions

G. Wilding, J. Grem, D. Spriggs, 1992, Cancer Chemotherapy and Pharmacology.

Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.

J. Grem, P. Fischer, 1985, Cancer research.

Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma.

J. Grem, C. Allegra, G. Aherne, 1998, Molecular pharmacology.

Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells.

J. Grem, C. Allegra, F. Balis, 1996, Biochemical pharmacology.

A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.

S. Steinberg, P. Johnston, S. Arbuck, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

National Institutes of Health consensus development conference statement: Management of hepatitis B

I. Gareen, G. Petersen, J. Grem, 2009, Hepatology.

Hypersensitivity reactions to trimetrexate

J. Grem, M. Costanza, T. Brown, 1990, Investigational New Drugs.

Levamisole as a therapeutic agent for colorectal carcinoma.

J. Grem, 1990, Cancer cells.

Recent insights into the molecular basis of intrinsic resistance of colorectal cancer: new challenges for systemic therapeutic approaches.

J. Grem, 1998, Cancer treatment and research.

Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool.

B. Moss, J. Grem, G. Katsafanas, 1997, Virology.

Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells.

J. Grem, V. Kao, Q. Ren, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors

S. Swain, J. Grem, M. Blackman, 2010, Evidence-based complementary and alternative medicine : eCAM.

Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

J. Willson, J. Grem, D. Trump, 1987, Cancer treatment reports.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

J. Meyerhardt, James D. Murphy, C. Willett, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract.

J. Grem, 1997, Current opinion in oncology.

Metastatic leydig cell tumor of the testis report of three cases and review of the literature

J. Grem, D. Trump, K. Gilchrist, 1986, Cancer.

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

Edward A Belongia, I. Gareen, G. Petersen, 2009, Annals of internal medicine.

Clinical toxicity associated with tiazofurin

B. Cheson, L. Rubinstein, J. Grem, 1990, Investigational New Drugs.

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.

S. Steinberg, B. Kramer, J. Grem, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxicity and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells.

J. Grem, C. Allegra, J. Trepel, 1994, Biochemical pharmacology.

Hypersensitivity reactions to deoxycoformycin

E. Eisenhauer, J. Grem, P. O'dwyer, 2004, Cancer Chemotherapy and Pharmacology.

Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.

S. Steinberg, J. Grem, C. Allegra, 1993, Advances in experimental medicine and biology.

NIH consensus development statement on management of hepatitis B.

I. Gareen, G. Petersen, J. Grem, 2008, NIH consensus and state-of-the-science statements.

Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials

B. Leyland-Jones, J. Grem, J. Plowman, 1987, Investigational New Drugs.

Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice

J. Grem, R. Mahato, Virender Kumar, 2016, Pharmaceutical Research.

Clinical Practice Guidelines in Oncology TM

M. Choti, J. Fleshman, C. Willett, 2009 .

Localized Colon Cancer, version 3.2013

M. Choti, C. Willett, C. Fuchs, 2013 .

Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

M. Choti, C. Willett, Yi-Jen Chen, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.

J. Meyerhardt, C. Willett, Yi-Jen Chen, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis

Brandon Da Silva, Edward J. Kim, D. Tuveson, 2017, Cell.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Pingfu Fu, C. Takimoto, H. Lenz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

L. Grochow, L. Neckers, C. Takimoto, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Ahmed Kamel, Howard S Hochster, Christopher G Willett, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Rectal cancer.

M. Choti, Yi-Jen Chen, C. Fuchs, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Rectal Cancer , Version 2 . 2018 Clinical Practice Guidelines in Oncology

J. Meyerhardt, James D. Murphy, C. Willett, 2018 .

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Quan P. Ly, R. Powers, L. Cantley, 2017, Cancer cell.

NCCN Clinical Practice Guidelines in Oncology: rectal cancer.

Christopher Willett, Michael A Choti, Krystyna Kiel, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion

C. Takimoto, J. Grem, W. Dahut, 2003, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenomics of Neurodegenerative Diseases: Roles in Personalized Medicines

J. Grem, R. Mahato, Rinku Dutta, 2017 .

Lower Gastrointestinal Cancer

J. Grem, 2001 .

NCCN clinical practice guidelines in oncology. Anal carcinoma.

M. Choti, J. Fleshman, J. Berlin, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.

S. Steinberg, S. Arbuck, J. Grem, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.

J. Grem, R. Mahato, Krishna Kattel, 2015, British journal of clinical pharmacology.

A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors

E. Szabo, J. Grem, G. Leonard, 2005, Clinical Cancer Research.

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

P. Catalano, A. Benson, J. Grem, 2018, Cancer.

A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.

S. Steinberg, P. Johnston, C. Takimoto, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.

J. Grem, P. O'dwyer, D. Trump, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2‘‐deocycoformycin after failure of alpha‐interferon in hairy cell leukemia

B. Cheson, J. Grem, S. Durrleman, 1989 .

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro.

C. Takimoto, J. Grem, C. Allegra, 1993, Biochemistry.

Determinants of trimetrexate lethality in human colon cancer cells.

P. Johnston, J. Grem, C. Allegra, 1994, British Journal of Cancer.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

J. Doroshow, C. Takimoto, J. Grem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous remission in diffuse large cell lymphoma

J. Grem, P. Carbone, J. H. Brandenburg, 1986 .

Modulation of Fluorouracil Cytotoxicity by Interferon- a and - g

J. Grem, C. Allegra, G. Aherne, 1998 .

The role of interferon-α as a modulator of fluorouracil and leucovorin

P. Johnston, J. Grem, C. Allegra, 1995 .

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Quan P. Ly, R. Powers, L. Cantley, 2017, Cancer cell.

C1 INH deficiency and angioedema: a spectrum of disease. Part one.

J. Weiler, J. Grem, P. Halverson, 1984, Annals of allergy.

Massive skeletal muscle invasion by lymphoma.

A. Neville, J. Grem, D. Trump, 1985, Archives of internal medicine.

The role of methotrexate in osteosarcoma.

R. Wittes, B. Leyland-Jones, J. Grem, 1988, Journal of the National Cancer Institute.

Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples.

C. Takimoto, J. Grem, W. Dahut, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma

Quan P. Ly, J. Meza, M. Hollingsworth, 2019, American journal of clinical oncology.

APhase IPharmacologic and PharmacogeneticTrial of Sequential 24-Hour Infusion of Irinotecan Followedby Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with SolidTumors

E. Szabo, J. Grem, G. Leonard, 2005 .

Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs

Y. Pommier, K. Paull, J. Grem, 2000, Cancer Chemotherapy and Pharmacology.

Antimetabolites

A. Chen, J. Grem, 1992, Cancer chemotherapy and biological response modifiers.

A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.

A. Chen, C. Takimoto, J. Grem, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.

J. Grem, J. Shapiro, B. Schuler, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase.

C. Takimoto, J. Grem, J. Shapiro, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil.

N. Petrelli, J. Grem, H. Douglass, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

J. Grem, G. Leonard, B. Schuler, 2005, BMC Cancer.

New concepts for the development and use of antifolates.

P. Johnston, J. Grem, C. Allegra, 1996, Stem cells.

New Concepts for the Development and Use of Antifolates

P. Johnston, J. Grem, C. Allegra, 1996, The oncologist.

Anal Carcinoma , Version 2 . 2018 Clinical Practice Guidelines in Oncology

J. Meyerhardt, A. Benson, James D. Murphy, 2018 .

Pentostatin in hairy cell leukemia: treatment by the special exception mechanism.

R. Wittes, B. Cheson, B. Leyland-Jones, 1989, Journal of the National Cancer Institute.

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine

J. Grem, K. Danenberg, P. Danenberg, 2008, BMC Cancer.

Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.

J. Grem, 2005, Seminars in oncology.

A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors

J. Grem, D. Northfelt, D. V. Hoff, 2007 .

Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer.

Justin M. Yurkovich, J. Grem, A. Berger, 2010, Oncology nursing forum.

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

J. Meyerhardt, A. Benson, C. Willett, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Colon Cancer , Version 3 . 2014 Clinical Practice Guidelines in Oncology

A. Benson, James D. Murphy, C. Willett, 2014 .

Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.

J. Grem, Yan Xu, B. Keith, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography.

J. Grem, Yan Xu, B. Keith, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.

G. Curt, J. Schlom, J. Grem, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule

E. Szabo, J. Grem, J. M. Hamilton, 2003, Cancer chemotherapy and pharmacology.

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

J. Bryant, N. Wolmark, J. Grem, 1998, Journal of the National Cancer Institute.

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.

S. Steinberg, S. Arbuck, R. Beveridge, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer.

P. Singh, J. Grem, A. Lazenby, 2017, Cancer research.

Adjuvant treatment of node-positive colon carcinoma with levamisole and 5-fluorouracil.

J. Grem, 1991, Oncology.

A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma

M. Borad, J. Grem, M. Mita, 2015, Cancer investigation.

Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

James D. Murphy, C. Willett, C. Fuchs, 2015 .

Neurocognitive function and quality-of-life in patients with colorectal cancer.

J. Grem, K. Schmid, E. Lyden, 2023, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.

R. Wittes, B. Leyland-Jones, J. Grem, 1988, Journal of Clinical Oncology.

Sequencing of treatment in advanced unresectable colorectal cancer.

J. Grem, 2013, The Journal of the National Comprehensive Cancer Network.

Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience.

J. Grem, 1992, Seminars in oncology.

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients

A. Chen, S. Arbuck, C. Takimoto, 2001, Cancer Chemotherapy and Pharmacology.

Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.

J. Willson, J. Grem, D. Trump, 1989, Cancer research.

Clinical Pharmacology of 9‐Aminocamptothecin

J. Grem, C. Allegra, J. M. Hamilton, 1996, Annals of the New York Academy of Sciences.

Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.

B. Levin, J. Grem, J. Abbruzzese, 1989, Journal of the National Cancer Institute.

Rectal Cancer, Version 2.2015.

James D. Murphy, C. Willett, Yi-Jen Chen, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

J. Meyerhardt, C. Willett, C. Sofocleous, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Engrailed-1 Promotes Pancreatic Cancer Metastasis

D. Tuveson, A. Borowsky, M. Hollingsworth, 2023, bioRxiv.

Brain metastasis and leptomeningeal carcinomatosis in a patient with cholangiocarcinoma.

J. Grem, B. William, 2011, Gastrointestinal cancer research : GCR.

Colon Cancer , Version 2 . 2018 Featured Updates to the NCCN Guidelines

J. Meyerhardt, James D. Murphy, C. Willett, 2018 .

Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography

J. Grem, C. Allegra, J. Drake, 1993, Anti-cancer drugs.

Why We Should Not Treat Patients with Stage II Colon Cancer

J. Grem, S. Subbiah, 2012, Current Colorectal Cancer Reports.

Relative gene expression in normal and tumor tissue by quantitative RT-PCR.

Ji Min Park, J. Grem, K. Danenberg, 2002, Methods in molecular biology.

Tumour extracellular vesicles and particles induce liver metabolic dysfunction

G. Wang, S. Batra, M. Hollingsworth, 2023, Nature.

Rectal cancer clinical practice guidelines in oncology.

M. Choti, T. Yeatman, C. Willett, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Spontaneous remission in diffuse large cell lymphoma

J. Grem, P. Carbone, J. H. Brandenburg, 1986, Cancer.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Quan P. Ly, R. Powers, L. Cantley, 2017, Cancer cell.

The saltz article reviewed

J. Grem, 2005 .

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Quan P. Ly, R. Powers, L. Cantley, 2017, Cancer cell.

NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines TM ) Rectal Cancer Version 1 . 2011

J. Grem, M. Mulcahy, J. Skibber, 2001 .